Heterocyclic inhibitors of protein arginine methyl transferases
申请人:Purandare Vinayak Ashok
公开号:US20060235037A1
公开(公告)日:2006-10-19
A compound of formula I, or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or solvate thereof,
methods of using such compounds in the treatment of hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases; and to pharmaceutical compositions containing such compounds.
Base‐Catalyzed Sequential 5‐
<i>exo</i>
‐dig/7‐
<i>endo</i>
‐dig Cyclization of (2‐Alkynylphenyl) Benzyl Ethers: Scope, Mechanism Studies, and Photophysical Properties
作者:Roberto do Carmo Pinheiro、Luiz Eduardo Welter、Bernardo A. Iglesias、Davi F. Back、Luiza Souza Marques、Cristina Wayne Nogueira、Gilson Zeni
DOI:10.1002/ejoc.202200984
日期:2022.10.20
Heterocycles fused to seven-memberedrings are synthesized in a highly selective fashion from (2-alkynylphenyl) benzyl ethers by a consecutive potassium tert-butoxide-catalyzed one-pot cyclization.
Electrophilic Cyclization of 2-Chalcogenealkynylanisoles: Versatile Access to 2-Chalcogen-benzo[<i>b</i>]furans
作者:Flávia Manarin、Juliano A. Roehrs、Rafaela Mozzaquatro Gay、Ricardo Brandão、Paulo H. Menezes、Cristina W. Nogueira、Gilson Zeni
DOI:10.1021/jo802736e
日期:2009.3.6
An efficient synthesis of 2-chalcogen-3-substituted-benzo[b]furan compounds has been accomplished via electrophilic cyclization reaction of 2-chalcogenealkynyl anisoles using I-2, ICl, Br-2 and PhSeBr as electrophile sources. The product distributions were strongly dependent on the nature of substituents in the aromatic ring of anisole and on the chalcogen atom directly bonded to the triple bond. The 2-chalcogen-3-iodo-benzo[b]furans obtained smoothly underwent conversion to more complex structures of benzo[b]furan derivatives via palladium- or copper-catalyzed cross-coupling reaction with thiols, diphenyl diselenides, and zincates.
[EN] HETEROCYCLIC INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASES<br/>[FR] INHIBITEURS HETEROCYCLIQUES DES PROTEINES ARGININE METHYLE TRANSFERASES
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2006113458A1
公开(公告)日:2006-10-26
[EN] A compound of formula I, or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or solvate thereof, methods of using such compounds in the treatment of hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases; and to pharmaceutical compositions containing such compounds. [FR] Composé de formule I, ou un de ses stéréoisomères, de ses tautomères, de ses sels pharmaceutiquement acceptables ou de ses solvates, méthodes d'utilisation de tels composés pour le traitement de troubles et de maladies hyperproliférantes, inflammatoires, infectieuses, et immunomodulatrices ; et compositions pharmaceutiques contenant de tels composés.